ALX Oncology initiated with a Buy at UBS [Yahoo! Finance]
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Yahoo! Finance
combo currently in Phase II for metastatic breast cancer, the analyst tells investors in a research note. UBS sees ALX reporting a “robust” dataset in mid-2027, demonstrating CD47 inhibitor evorpacept's efficacy in CD47 high and/or HER2+ metastatic breast cancer patients. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now See today's best-performing stocks on TipRanks Read More on ALXO: Disclaimer & Disclosure Report an Issue ALX Oncology reports Q4 EPS (42c), consensus (36c) ALXO Earnings this Week: How Will it Perform? ALX Oncology price target raised to $4 from $3 at Piper Sandler ALX Oncology announces major underwritten public equity offering ALX Oncology Highlights Biomarker Data a
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology (ALXO) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $5.00 price target on the stock.MarketBeat
- ALX Oncology (ALXO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- ALX Oncology (ALXO) is now covered by UBS Group AG. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update [Yahoo! Finance]Yahoo! Finance
- ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones [Seeking Alpha]Seeking Alpha
ALXO
Earnings
- 2/27/26 - Miss
ALXO
Sec Filings
- 3/9/26 - Form 10-K
- 3/5/26 - Form 4
- 3/5/26 - Form 3
- ALXO's page on the SEC website